Leukemia Clinical Trials

Showing 901-920 of 10,987 trials

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

NCT07356544

The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice. The enrolment will start in September 2024 until September 2025. A 12-months follow-up window will be performed.

NSCLC (Advanced Non-small Cell Lung Cancer)HER2

Gruppo Oncologico Italiano di Ricerca Clinica50 participantsStarted Aug 2025

Bari, BA, Italy • Meldola, FC, Italy • Ferrara, FE, Italy +19 more locations

Active Not RecruitingPhase 3

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

NCT04075292

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Untreated Chronic Lymphocytic Leukemia

AstraZeneca155 participantsStarted Jan 2020

Beijing, China • Changchun, China • Changsha, China +43 more locations

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Related Searches

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Cervical Strength, Proprioception and Performance in Adolescent Soccer

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Palliative Thoracic ImmunoRT

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia